|
Electronic product information: new report shows it is time to move from principles to action |
Medicines for Europe |
25 Feb 2022 |
Health & Consumers |
|
EMA clarifies no scientific evidence to deter use of ibuprofen to manage coronavirus symptoms |
Medicines for Europe |
18 Mar 2020 |
Health & Consumers |
|
EMA/HMA share definitive EU-wide position on biosimilar medicines interchangeability |
Medicines for Europe |
20 Sep 2022 |
Health & Consumers |
|
Energy Council (TTE) – Medicines for Europe Open letter to European Energy Ministers and responsible European Commissioners on inflation and energy costs impacting the supply of essential generic medicines |
Medicines for Europe |
28 Sep 2022 |
Health & Consumers |
|
EU can do more for equitable access to medicines |
Medicines for Europe |
13 Jan 2023 |
Health & Consumers |
|
EU can do more for patients with smart use of biosimilar medicines |
Medicines for Europe |
29 Apr 2022 |
Health & Consumers |
|
EU digital strategy requires investments in the digitalisation of Europe’s medicines regulatory agencies to succeed |
Medicines for Europe |
15 Jan 2021 |
Health & Consumers |
|
EU industrial policy can dramatically improve medicines manufacturing resilience and security of supply |
Medicines for Europe |
17 Mar 2021 |
Health & Consumers |
|
EU Industrial strategy should be key to improving medicines supply chains |
Medicines for Europe |
17 May 2021 |
Health & Consumers |
|
EU manufacturers call for urgent reforms to achieve reciprocity and a level-playing field in public procurement |
Medicines for Europe |
30 Sep 2019 |
Health & Consumers |
|
EU must address barriers to continuous off-patent innovation and grasp opportunity for patients and healthcare |
Medicines for Europe |
23 Feb 2021 |
Health & Consumers |
|
EU must bolster biosimilar medicines policy to increase equity of access and bring much needed savings to healthcare budgets |
Medicines for Europe |
25 May 2023 |
Health & Consumers |
|
EU must learn from Covid-19 to improve crisis preparedness and response for the future |
Medicines for Europe |
09 Nov 2021 |
Health & Consumers |
|
EU must take the lead to ensure security of supply for medicines |
Medicines for Europe |
16 Jun 2021 |
Health & Consumers |
|
EU pharma strategy success depends on access to generic, biosimilar and value added medicines |
Medicines for Europe |
25 Nov 2020 |
Health & Consumers |
|
EU Pharmaceutical Strategy Roadmap: high time to improve patient access to medicines and to apply the lessons from COVID-19 |
Medicines for Europe |
04 Jun 2020 |
InfoSociety |
|
EU Semester Country Specific Recommendations: Improve patient access to medicine and ensure healthcare sustainability |
Medicines for Europe |
24 May 2018 |
Health & Consumers |
|
EU Semester Country Specific Recommendations: More Efficient Medicine Policies Needed for Patient Access |
Medicines for Europe |
23 May 2017 |
Health & Consumers |
|
European Commission launches: “What I need to know about Biosimilar Medicines - Information for patients”, in 23 EU languages |
Medicines for Europe |
29 Nov 2017 |
Health & Consumers |
|
European Commission pilot project on repurposing brings value added innovation to life |
Medicines for Europe |
28 Oct 2021 |
Health & Consumers |
|
European Health Union – first step to greater EU solidarity in health crisis situations |
Medicines for Europe |
11 Nov 2020 |
Health & Consumers |
|
European Organisation for Specialised Nurses (ESNO) launches switch management guide between similar biological medicines - a guide for nurses |
Medicines for Europe |
26 Jun 2018 |
Health & Consumers |
|
European Parliament report calls for increased use of off-patent medicines to improve patient access |
Medicines for Europe |
25 Nov 2021 |
Health & Consumers |
|
European patients need improved access to biosimilar medicines |
Medicines for Europe |
22 Apr 2021 |
Health & Consumers |
|
Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit |
Medicines for Europe |
28 Nov 2017 |
Health & Consumers, UK in Europe |
|
Failure to launch: white paper explores the role of inappropriate use of IP in blocking access to generic and biosimilar medicines |
Medicines for Europe |
05 Nov 2020 |
Health & Consumers |
|
Fulfilling the Biosimilar Promise: Report Highlights Key Principles in Support of a Sustainable Market |
Medicines for Europe |
19 Sep 2016 |
Health & Consumers |
|
Future of pharmaceutical policy rests on secure supply of essential medicines |
Medicines for Europe |
03 May 2023 |
Health & Consumers |
|
Generic & biosimilar medicines pivotal for safe, effective and affordable access to medicines in Europe |
Medicines for Europe |
28 Nov 2019 |
Health & Consumers |
|
Giving medicines a new life: EU should foster patients’ access to Value Added Medicines |
Medicines for Europe |
30 Nov 2022 |
Health & Consumers |
